Infliximab for chronic cytoid macular edema aociated with uveiti

Purpoe To ae the efficacy of the anti-TNF monoclonal antibody infliximab in uveiti patient without clinically evident ocular inflammation and impaired viual acuity becaue of chronic cytoid macular edema (CME). Deign Propective, noncomparative, interventional cae erie. Method Patient with refractory CME (14 eye, mean duration of 14 month), aociated with intermediate uveiti (n = 6), Adamantiade-Behcet dieae (n = 2), adult-type vacular peudotumor (n = 1), and HLAB27+-related uveiti (n = 1) received an intravenou infliximab infuion (5 mg/kg); five patient were retreated after 1 month. Reult Macular thickne, meaured by ocular coherence tomography, wa reduced from 428 ± 138 μm to 219 ± 51 μm at 2 month potbaeline (P = .0001), while viual acuity increaed from 0.41 ± 0.18 to 0.83 ± 0.17 (P < .00001). Anatomic and functional improvement wa utained at 6 month in all. No ocular or extra-ocular ide effect were noted. Concluion Thee promiing reult ugget that TNF may play an important pathogenetic role in chronic CME, thu, a controlled trial i warranted.